title: The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study).
abstract: OBJECTIVE
  To determine if therapeutic management programmes for type 2 diabetes that include self-monitoring of blood glucose (SMBG) result in greater reductions in glycated haemoglobin (HbA1c) compared with programmes without SMBG in non-insulin requiring patients.
  
  
  METHODS
  Multicentre, randomized, parallel-group trial. A total of 610 patients were randomized to SMBG or non-SMBG groups. Patients in both groups received the same oral antidiabetic therapy using a gliclazide modified release (MR)-based regimen for 27 weeks. The primary efficacy end-point was the difference between groups in HbA1c at the end of observation.
  
  
  RESULTS
  A total of 610 patients were randomized: 311 to the SMBG group and 299 to the non-SMBG group. HbA1c decreased from 8.12 to 6.95% in the SMBG group and from 8.12 to 7.20% in the non-SMBG group; between-group difference was 0.25% (95% CI: 0.06, 1.03; p = 0.0097). Symptoms suggestive of mild to moderate hypoglycaemia was the most commonly reported adverse event, reported by 27 (8.7%) and 21 (7.0%) patients in the SMBG and non-SMBG groups, respectively; the incidence of symptomatic hypoglycaemia was lower in the SMBG group.
  
  
  CONCLUSIONS
  In patients with type 2 diabetes, the application of SMBG as an adjunct to oral antidiabetic agent therapy results in further reductions in HbA1c.
authors.affiliation: Department of Medicine, University of Birmingham, Birmingham Heartlands Hospital, Birmingham, UK. anthony.barnett@heartofengland.nhs.uk
authors.forename: A H
authors.initials: AH
authors.lastname: Barnett
authors.forename: A J
authors.initials: AJ
authors.lastname: Krentz
authors.forename: K
authors.initials: K
authors.lastname: Strojek
authors.forename: J
authors.initials: J
authors.lastname: Sieradzki
authors.forename: F
authors.initials: F
authors.lastname: Azizi
authors.forename: M
authors.initials: M
authors.lastname: Embong
authors.forename: S
authors.initials: S
authors.lastname: Imamoglu
authors.forename: J
authors.initials: J
authors.lastname: Perusicová
authors.forename: V
authors.initials: V
authors.lastname: Uliciansky
authors.forename: G
authors.initials: G
authors.lastname: Winkler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin